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… Mientras haya unos ojos que reflejen  
     los ojos que los miran,  
    mientras responda el labio suspirando  
    al labio que suspira,  
    mientras sentirse puedan en un beso  
    dos almas confundidas,  
    mientras exista una mujer hermosa,  
    habrá poesía ! 
 
                                                                                 Gustavo Adolfo Becquer 
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INTRODUCTION: 
 
1.1. CHOLINE METABOLIC PATHWAYS: 
In 1998, choline was identified as an essential nutrient for humans by the National 
Academy of Sciences, United States (1). Choline (trimethyl-β-hydroxy-ethylammonium) is 
a quaternary amine linked to a two carbon atoms backbone with an alcoholic moiety (2) 
and its concentration in plasma has a physiological range of 10–50 µM (3). Choline is 
predominantly utilized for the synthesis of essential lipid components of the cell 
membranes, phosphatidylcholine (PCh) and sphingomyelin, and for the production of 
potent lipid mediators such as platelet-activating factor and lysophosphatidylcholine (4). 
Quantitatively, PCh is the most important metabolite of choline and accounts for approx- 
imately one-half of the total membrane lipid content (5). Similarly to folate, choline is a 
source of labile methyl groups (6). In the liver and kidney mitochondria, choline is oxidized 
to betaine (trimethylglycine), which then enters the one-carbon cycle and serves as a 
methyl donor in the re-methylation of homocysteine to methionine, to ultimately generate 
the methylation agent S-adenosylmethionine (7). Finally, choline is best known for its key 
role in neurons as the precursor of the neurotransmitter acetylcholine (8, 9). Acetylcholine 
could also be synthesized and released from non-neuronal cells; however, its role outside 
of neurons is not clearly defined (10). The choline metabolic pathways are resumen in 
figure 1, while, in figure 2 an overview with molecular structures is shown. 
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Figure 1: Choline metabolic pathways. ADP, adenosine diphosphate; ATP, adenosine triphosphate; BHMT, 
betaine:homocysteine methyltransferase; B12, vitamin B12; CDP, cytidine diphosphate; CK, choline kinase; 
CPT, CDP-choline:DAG cholinephosphotransferase; CMP, cytidine monophosphate; CTP, cytidine 
triphosphate; DAG, diacylglycerol; MAT, methionine adenosyltransferase; methylTHF, 5 
methyltetrahydrofolate; MS, methionine synthase; MTHF, 5,10-methylene-tetrahydrofolate; PAF, platelet 
activating factor; PCP, phosphatidylcholine: ceramidecholine phosphotransferase; Pcyt1, 
CTP:phosphocholine cytidyltransferase; PEMT, phosphatidylethanolamine N-methyltransferase; PLA, 
phospholipase A2; PPi, pyrophosphate; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; THF, 
tetrahydrofolate. The figure is printed from (11). 
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Figure 2 Metabolic fate of choline. 
 
The majority of cellular choline is phosphorylated by choline kinase (ChK) to 
phosphocholine, then CTP can then be added to phosphocholine by Pcyt1 to yield CDP-
choline. The formation of PCh results from the reaction of CDP-choline with diacylglycerol 
(DAG), catalyzed by the enzyme CDP-choline DAG cholinephosphotransferase (CPT, Fig. 
1). This pathway is known as the Kennedy (CDP-choline) pathway for de novo synthesis of 
PCh and is essential for the formation of membrane PCh in all nucleated cells. Since its 
discovery in the 1950s by Eugene Kennedy, this pathway has been extensively studied, 
and most aspects of its regulation are well established. In recent years, focus is more on 
cloning and characterization of genes participating in the pathway (12–16), with emphasis 
on the rate-regulatory gene Pcyt1 (17-19); the Kennedy pathway is not considered to be 
regulated by other steps in the pathway, nor by the rate of choline transport. 
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During evolution, the liver has retained a backup pathway for choline production from the 
second most abundant membrane phospholipids, phosphatidylethanolamine (PE, Fig. 1), 
to provide this essential metabolite when dietary choline is limited, as, for example, during 
starvation, embryonic development, pregnancy, or lactation. PE is transformed to PCh in a 
three-step methylation by SAM, which is catalyzed by phosphatidylethanolamine-N-
methyl-transferase (PEMT). The PE methylation pathway has been extensively studied by 
Dr. Dennis Vance and his collaborators (20, 21). More recently, his laboratory developed a 
PEMT knockout mouse model, providing valuable data on the role of this pathway in the 
liver, PCh synthesis, lipoprotein secretion, and bile and homocysteine production (15, 22). 
 
1.2. CHOLINE TRANSPORT: 
Choline is a positively charged quaternary amine and requires a protein-mediated 
mechanism to effectively pass the membrane lipid barrier. The mechanisms underlying 
choline transport have not been completely elucidated; however, three protein-mediated 
and thus saturable uptake systems, following Michaelis-Menten kinetics, are well 
documented (23–28). 
The first mechanism is the facilitated diffusion that has an apparent Km of 10 µM of choline, 
driven by a choline concentration gradient as described in red blood cells (24).  
The second is a high-affinity, Na+- and energy-dependent transport system with a Km of 
0.5–3 µM that is sensitive to inhibition by low concentration of hemicholinium-3 (HC-3, Ki of 
1–3 µM; Ref. 25). This ‘‘active transport’’ system is coupled to the biosynthesis of 
acetylcholine and is primary to neuronal tissues (25).  
The third, also ‘‘active transport,’’ system, which is somewhat lower in affinity for choline 
(Km ca. 20–200 µM), is ubiquitously distributed, and less effectively inhibited by HC-3 (Ki 
ca. 20–200 µM) than the neuronal system (26–28). This system operates in most cells as 
a means of choline uptake for the purpose of phospholipid synthesis. 
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1.3. CHOLINE METABOLISM AND MALIGNANT TRANSFORMATION: 
Choline metabolism and choline-derived metabolites can undergo extensive alterations as 
a result of a malignant transformation. The level of phospocholine in human breast cancer 
cells was found to be markedly higher than in normal human mammary epithelial cells (29- 
31). Both choline transport and phosphorylation were found to be augmented in human 
breast cancer cells relative to their normal counterpart. The level of phosphocholine 
correlated with the maximal rate of choline transport in the normal and cancerous cells, but 
it did not correlate with the tumorgenecity and invasiveness of the cancer cells. 
Progression of human mammary epithelial cells from a normal to a malignant phenotype 
was shown to be associated with a reversion in the balance, as well as an overall increase 
in the content of phosphocholine and GPCho (31). A similar trend was also exhibited by 
human prostatic epithelial cells (32). High levels of phosphomonoesters, including 
phosphocholine, were detected in human breast cancer biopsies and patients (33-35). Ras 
transformed cells, and multi oncogenic transformed cells have also exhibited an increase 
in phosphocholine content (36-38). Choline-kinase activation was shown to be critical for 
the proliferation of primary human mammary epithelial cells and breast tumors progression 
(39). Indeed, cessation of phosphocholine synthesis by novel choline kinase inhibitors 
exhibited antitumor activity (40-42).  
Choline is a precursor of choline derived phospholipids, but can be also recovered as a 
product of their hydrolysis. The synthesis and degradation of phospholipids may be 
induced by growth factors that play a major role in malignant transformations (43, 44). 
Several studies have demonstrated regulation of PCh metabolism by a receptor tyrosine 
kinase cascade, downstream of the ras/raf interaction (45, 46). In turn, molecules derived 
by the breakdown of choline-containing-phospholipids, such as diacylglycerol, ceramide, 
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and phosphocholine can act as second messengers in mitogenic signal transduction 
pathways (47-50). 
 
1.4. POSITRON EMISSION TOMOGRAPHY TUMOURS IMAGING BY MEANS OF 
CHOLINE BASED TRACERS: 
Tumor imaging with choline-based tracers was introduced by Hara and coworkers using 
carbon-11 (11C) choline PET to successfully visualize brain tumors and prostate cancer 
(51,52). As a true tracer, 11C choline is biochemically indistinguishable from natural 
choline. This compound has shown particular promise for imaging tumours of the 
genitourinary tract because of its limited urinary clearance and avidity for bladder and 
prostate cancers (53-58). However, the short decay half-life of the carbon-11 (20 minutes) 
has limited its use to centers equipped with an on-site cyclotron. 
Conversely, 18F is a radionuclide with optimal decay characteristics both for PET 
applications and for a widespread utilization. For these reasons, [18F]-labeled analogues 
have been developed and tested as an alternative choline derivatives for PET imaging of 
prostate and brain tumours (59-61). Among the analogues the most used are also in 
clinical practice are [18F]fluoromethyl-dimethyl-2-hydroxy-ethylammonium (18FCH) and 2-
[18F]-fluoroethylcholine (18FECH). In figure 3 are shown some choline analogues labelled 
with 18-Fluoro and 11C-Choline for comparison. Figure 3 is derived from (64). 
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Figure 3. Chemical structure of positrons emitters – labelled choline analogues. 
 
 The sterical hindrance and structural features imparted by the introduction of a fluorine 
atom in the choline backbone have been thoroughly investigated both in vitro and in vivo 
(62–65). In these studies, it was reported that two methyl groups on the quaternary amine 
are essential for maintaining the affinity of the molecule for the choline transport system 
and for the specificity of choline kinase. The remaining third methyl group can be replaced 
by a longer alkyl chain where an 18F atom is linked. 
At the present time, it is not known which choline derivative is most advantageous for 
clinical use. There have been no direct in vivo comparisons between individual com- 
pounds, and previous in vitro comparisons have not controlled for potentially confounding 
factors, including the presence of synthetic contaminants such as dimethylethanolamine, 
which may modulate the phosphorylation and trans- port of these compounds in vitro. 
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As a result, the syntheses of 18FCH and 18FECH were developed in two-step reactions. 
Both the procedures resulted rather complicate to be carried out in an hospital 
environment and required time consuming purifications by means of gas chromatography 
(GC) or high-performance liquid chromatography (HPLC) (64,65). In figure 4 are shown 
the different precursors and purification methods that have been reported in literature. 
 
X
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F18
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F18
N
+
OH
Transfer phase catalyst ( b )
Solvent ( c )
Precursor ( a ) 18F-Fluoroethylating agent ( d )
Purification ( e )
DMAE  
Solvent ( f ) Purification ( g ) 18F-ECH
( a, d )  X = Br, OTs, OTf   Y =  Br, OTs   ( b ) TBAHCO3 or Kry 2.2.2   ( c ) ACN, o-DCB, DMSO
( e ) nothing, GC, distillation, SPE   ( f ) nothing, ACO, ACN, DMSO, DMF  ( g ) SPE, HPLC, SPE + HPLC
                                  
 
Figure 4 : 18FECH syntheses using different reagents, solvents and purification methods 
 
The choline metabolite peak on magnetic resonance spectroscopy (MRS) also has been 
proposed as an indicator of malignancy or proliferation (66). However, correlations 
between 18F-FCH or 11C-choline uptake on PET and choline metabolite concentrations on 
MRS have not always been observed, alluding to the possibility that increased choline 
spectral peaks on MRS may not specifically reflect free choline or the active accumulation 
of choline metabolites by cells (67,68). For example, in the case of a tumefactive 
demyelinating lesion, where increases in choline metabolite concentrations are frequently 
observed with MRS (presumably due to demyelination), there may not be corresponding 
increases in the uptake of 11C choline or 18F-FCH (68,69). In malignant glial tumours, 
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where mitogenic activity would be expected to result in the active utilization of choline, a 
direct regional correlation has been observed between 18F-FCH uptake and choline 
metabolite peaks on spectroscopy (68). Without a better understanding of the biochemical 
basis of what is measured by both MRS and choline-based PET imaging, it will be difficult 
to integrate this information for clinical purposes (65). Because there is occasional 
discordance, there will most likely be complementary value to both measures. 
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2. AIM: 
 
The first purpose of this dissertation was to develop a reliable synthesis of 18FECH by 
using commercial synthesizers. Different synthetic approaches, reaction parameters, and 
purification methods were compared and optimized in order to achieve the highest 
radiochemical yield and purity. Aiming at a user- friendly and widely applicable procedure, 
the use of commercial reagents and the feasibility of a one-pot reactions and SPE 
purification were assessed.  
Although 18F-FECH is a radiopharmaceutical widely used in the clinical practice for the 
detection of prostate cancer recurrence and brain tumours by PET (11, 70), it is still 
subjected to  experimental protocols because no Monographs is present on the European 
Pharmacopeia. For this reason the second purpose of this dissertation is to establish a 
what techniques and instruments are necessary for assessing the suitability of the 18FECH 
preparations in humans. quality controls. For this reason, with no regard for the synthetic 
procedure, the final 18FECH solution was submitted to an in-depth set of quality controls 
for attesting the reliability of the synthesis and for evaluating a safe employment of the 
radiotracer for clinical trials.  
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3. EXPERIMENTAL: 
 
3.1. 2-[18F]-FLUOROETHYLCHOLINE SYNTHESIS: 
In recent years, the synthesis of 18FECH has been the most investigated of the [18F]- 
radiolabelled choline derivatives likely because its synthesis was supposed to allow for 
easier automation. In the original method (65), [18F]fluoride was reacted with a 1,2-bis 
(tosyloxy)ethane (diOTsEt) solution to give [18F]fluoro-ethyltosylate (18FEtOTs). 
Subsequently, a large excess of pure N,N-dimethylaminoethanol (DMAE) was added di- 
rectly to the mixture in order to obtain 18FECH. The reaction mixture was purified by 
evaporation, HPLC and then solid-phase extraction (SPE) obtaining the product with a 
27% radiochemical yield (RCY), not decay corrected. This approach was recently 
improved with a fully automated synthesis and a yield of 36% was achieved (71). In other 
studies, different [18F]-fluoroethylating agents (18FEtX) were obtained by nucleophilic 
substitution on various precursors and reacted with DMAE solutions (72,73). However, in 
those studies, at least one SPE purification after the nucleophilic substitution and an HPLC 
purification after the alkylation reaction were performed. In spite of this and with some 
minor changes in the first described approach (65), Zuhayra et al. were able to synthesize 
18FECH with a 47% RCY (not decay corrected) (72). However, the use of a non-
commercial precursor and of toxic solvent such as 1,2-dichlorobenzene is a strong 
drawback for applying this method in a clinical setting. Recently, it was reported that a 
drastic increase in [18F] fluoroethylating agents yield could be obtained by adding alkali 
iodide to the reaction mixture (73). However, when 18FECH synthesis was fully performed 
using that approach, only a 30% of RCY was obtained (74). Schmaljohann J et al. reported 
a 18FECH synthesis in two steps and high yield by starting from BrEtONos precursor but 
the assessment of the chemical purity of the preparation was not completely fulfilled as 
only an UV detector was used in the HPLC analysis for quality control (75). 
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3.2. MATERIALS AND METHODS: 
3.2.1 Reagents: 
diOTsEt, DMAE, dibromoethane, ethanol and dry acetonitrile (ACN) were purchased from 
Sigma-Aldrich (Milan, Italy). Tetra-butylammonium bicarbonate (TBA) and Kryptofix 2.2.2/ 
K2CO3 solutions as well as 1,2-bis(nosyloxy)ethane (diONsEt), 2-Bromoethyltosylate 
BrEtOTs were obtained by ABX (Radeberg, Germany). Fluoroethylcholine chloride (FECH) 
and N,N-dimethylmorpholinium chloride (diMMCl), used as reference standards for the 
quality controls, were purchased from ABX and Labotest OHG (Dresden, Germany), 
respectively. All the reagents were used without further purification. Unless otherwise 
specified, the water used in any operation was distilled by using a MilliQ Simplicity 185 
(Millipore, Milan, Italy). Sep-Pak light QMA (preconditioned CO32- form), Sep-pak plus 
QMA, plus C-18 and CM cartridges were obtained by Waters (Milan, Italy). Cathivex- GS 
0.22-µm filters were purchased from Millipore. 
 
3.2.2. Instrumentations: 
No-carrier-added [18F]fluoride was produced by the 18O (p,n)18F nuclear reaction on a 
MINItrace cyclotron (GE Medical system, Uppsala Sweden) using a 9.6 MeV proton beam. 
Enriched (> 98 %) [18O]water was purchased from SRICI (Shanghai, China).  
 
3.2.2.1. Automatic synthesizers:  
An automated synthesis/dispense module is defined as an electromechanical device 
controlled by software to automatically perform a sequence of operations needed to 
synthesise and/or formulate and/or dispense a radiopharmaceutical. It usually consists of a 
combination of power supplies, actuators, pumps, heaters and sensors that are used in 
combination with an interconnected network of containers, reactors, tubing, syringes, solid 
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phase cartridges and/or preparative HPLC systems. The automated synthesis/dispense 
module can be a commercial piece of equipment or can be custom made. It is common for 
different radiopharmaceuticals to be made on the same automated synthesis/dispense 
module. Within the synthesis process, the automated synthesis/dispense module controls 
the mixing of starting materials and reaction parameters in such a way that a bulk solution 
of a radiopharmaceutical is produced. The containers and purification system used with 
the automated synthesis/dispense module can be single-use (‘radiopharmaceutical 
cassette’) or used in multiple production runs. It must be shown by appropriate cleaning 
protocols that the quality of the produced radiopharmaceutical is not negatively affected 
when used in multiple production runs. Cross contamination must be prevented. The 
containers and purification systems (i.e. the column of a preparative HPLC system) are 
considered part of the synthesiser. The electronic components of the synthesiser are 
usually resistant to high radiation. Components that come into contact with the starting 
materials, solvents and/or the radiopharmaceutical are chemically inert.  Automated 
dispensing modules control formulation and dispensing of the radiopharmaceutical. This is 
usually done by using volume- or weight-measuring devices and radioactivity detectors in 
order to measure and dispense the correct quantities. For dispensing, single-use tubing 
systems should be used unless a validated cleaning protocol is performed. The measuring 
systems are calibrated. The synthesis process on the synthesiser is usually controlled by 
software containing specific time lists for each process. Automated systems may involve 
the use of radiopharmaceutical cassettes. A radiopharmaceutical cassette is defined as a 
system of single-use production hardware (such as tubes, valves and filters). It is used 
with a set of starting materials (such as precursors, solvents, catalysts, etc.) which may be 
contained in the cassette or provided separately (prefilled vs. empty cassette). In order to 
maintain a low bacterial endotoxin level and achieve a high sterility assurance level for the 
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radiopharmaceutical prepared with the use of a cassette, the cassette have a low bio-
burden (76).  
In this dissertation, synthesis of 18FECH was accomplished by using two different 
automatic synthesizers. The first one, was an FX FN Tracer lab (GE Medical System, 
Uppsala, Sweden) without any modification from the original set up. F-X FN Tracer Lab is 
a multiple production synthesizer and an appropriate sequence of washing was adopted 
after every production.  
The second synthesizer was a Mx Tacerlab (GE Medical System, Uppsala, Sweden), 
namely a cassettes based synthesizer. The advantages and drawbacks of both 
synthesizer in the preparation of 18FECH will be described in the discussion session.  
 
3.2.2.2. Quality controls instruments: 
Radioactivity measurements were performed in a calibrated ion chamber (Aktivimeter 
ISOMED 2000, MED Nuklear- Medizintechnik, Dresden, Germany). The radiochemical 
and chemical purity of the 18FECH solutions were assessed by means of: (1) ion 
chromatography using an isocratic pump (Gilson, Milan, Italy) equipped with a Waters 432 
conductimeter (Waters, Milan, Italy) in series with a β+- flow count detector (Bioscan, 
Washington, DC) and with a 152 UV/VIS detector (Gilson, Milan, Italy); (2) Acquity UHPLC 
system with a binary solvent and auto-sampler manager modules (Waters, Milan, Italy). 
The instrument was equipped with an Acquity TUV detector (Waters) in series with  a 
Herm LB 500 radiochemical detector (Berthold Technologies, Milan, Italy) and a Waters 
432 conductimeter (Waters, Milan, Italy). The HPLC system was replaced with the UHPC 
system and the analysis method was further improved in order to obtain a complete 
assessment of the chemical and radiochemical composition of the final preparations: 
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Thin-layer chromatography (TLC) using an AR 2000 Imaging Scanner (Bioscan, 
Washington, DC, USA) and silica gel plates 60 F254 (Merck, Milan, Italy) was also 
performed. 
Residual solvents amounts and chemical purity were also measured by gas 
chromatography on a FOCUS GC system (Thermo Scientific, Waltham, MA, USA) 
equipped with a flame ionization detector (FID) and an AI/AS 3000 series auto-sampler. 
The absence of bacterial endotoxin in the final radiopharmaceutical preparations was 
checked with a chromogenic limulus amebocyte lisate test performed with an Endosafe-
PTS instrument (Charles Rives Laboratories, Charleston, SC, USA). 
Nuclear Magnetic Resonance spectrometer Bruker Avance 300 (Bruker, Milan, Italy) was 
used for acquiring 1H NMR spectra in order to assess the stability of the reagents. 
 
3.2.3. Radiopharmaceutical synthesis: 
3.2.3.1. TRACERlab Fx F-N: 
TRACERlab™ FX F-N (figure 5) is an 
automated versatile synthesizer for easy 
and efficient production of [18F] tracers 
via nucleophilic substitution with [18F] F-
Fluoride trapped from [18O] water. 
Purification of the products can be 
achieved by an integrated, preparative 
HPLC system. The system is based on 
a number of glassy reservoir and vessel 
connected by silicon tubing through two 
or three-ways valves. The flow of the liquid inside the synthesizer is regulated by an 
helium stream or by a mechanical vacuum pump. Reactions can be performed in a fixed 
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glassy carbon reactor where the temperature can range between 200 to RT °C. A rapid 
tempering of the liquids in the reactor is also allowed by a helium flow directed on the 
reactor body. Solid phase extraction cartridges can be put on line in varying positions. 
Through application software, all process steps are easily programmed to produce the 
required tracers. After every synthesis, Fx F-N have to be cleaned by  automatic rinsing 
protocols. 
         
Figure 5: Hardware of an Fx-F-N TRACERlab (G.E.m.s) 
 
In this study, 18FECH was synthesized by two different approaches, following the paths 
shown in Figure 6. The first method is the two-step reaction already reported in literature 
(65). The second method is an innovative approach which allows the two reactions to be 
carried out simultaneously and that was developed by the author of this dissertation (77). 
Moreover, two different methods for purifying the crude 18FECH solution (preparative 
HPLC and SPE) were used and compared. 
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Figure 6: the two approaches for the 2-[18F]-fluoroethycholine synthesis developed on the Fx F-N  
 
3.2.3.1.1 [18F]Fluoride production 
Batches of 2035 MBq [18F]fluoride were produced by irradiating [18O]water with a 25 µA 
current for 5 min. At the end of bombardment, the activity was transferred to the 
synthesizer and trapped into a light QMA cartridge. [18F] Fluoride was then desorbed from 
the cartridge by using alternatively a 0.075 M TBA bicarbonate solution (600 µl) or a Kry 
2.2.2 (22 mg)/K2CO3 (7 mg) ACN/water solution (50/ 50, v/v, 600 µl) as a phase transfer 
catalyst and directed into the reactor vessel. The reaction mixture was heated to dryness 
at 60 °C for 7 min and then at 120°C for 5 min. 
 
3.2.3.1.2. Two-step reaction 
To obtain the 18FEtOTs intermediate, a diOTsEt solution in ACN was added to the reaction 
vessel and heated for 5 min at 80°C. The temperatur e was cooled to 55°C and 18FEtOTs 
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was subsequently reacted with a DMAE solution in ACN for 10 min at 100°C. The reaction 
was performed in the same vessel, without carrying out any purification between the two 
steps. The effects on the yield of different phase transfer catalysts (TBA bicarbonate or Kry 
2.2.2) and different amounts of reagents were assessed. Moreover, the influence of the 
ACN volume in both steps was considered. 
 
3.2.3.1.3. One-step reaction 
The [18F]-fluoride production were carried out as described above, but only the TBA was 
used as a phase transfer catalyst. The nucleophilic substitution and the alkylation 
reactions were performed simultaneously by adding a solution of diOTsEt and DMAE 
dissolved in ACN to the [18F]-fluoride anhydrous residue. The reactor was heated at 95 °C 
for 10 min and then cooled to 50°C. As before, the effects of the reagents amounts and 
total ACN volume on the synthesis yield were assessed. In fact, when an unique heating 
step occurred, the reaction volume was directly given by the amount of ACN used for 
dissolving both the reagent. 
 
3.2.3.1.4. Purification of 18FECH 
After the synthesis, the reaction mixture was cooled to 50 °C and purified by following two 
different procedures:  
•   In the first one, reported by Hara et al. [65], the reactor vessel was rinsed with 4.5 
ml water for dissolving the reaction products. The solution was then injected into a 
semi-preparative HPLC (column: YMC–Pac ODS–A, flow rate: 5 ml/min and eluent: 
5⋅10−2 M H3PO4, 1⋅10−3 M 2-napthalenesulfonic acid). The separation was 
monitored by a β+-flow count detector and an ultraviolet (UV) detector in series. A 
three-way valve was switched in order to collect the selected 2 ml containing the 
purified fraction into a bulb vessel.  
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Figure 7:  Synoptic of the Fx F-N assembly when a preparative HPLC purification is performed.   
 
•   In the second approach, the reaction vessel was rinsed with 10 ml water. The 
washing solution, containing 18FECH, was filtered through two plus C-18 cartridges 
connected with two plus QMA cartridges and finally collected into a bulb vessel. 
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Figure 8:  Synoptic of the Fx F-N assembly when a SPE purification is performed.   
 
In both cases, the purified 18FECH was first transferred into a cation exchange cartridge 
(plus CM), then, the cartridge was washed out with 10 ml water and 5 ml ethanol. 
Subsequently the 18FECH was eluted with 3 ml 0.9% NaCl water solution and collected in 
the product vial. Before the final releasing, the preparation was filtered through a Cathivex-
GS 0.22-µm sterile filter and diluted with 12 ml 0.9 % NaCl water solution. 
Every synthesis and purification were carried out at least in triplicate. Either HPLC and 
SPE purification were carried out during the two step approach while only the SPE 
purification was performed in the one-step reaction. 
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3.2.3.2. Mx TRACERlab: 
TRACERlab MX FDG was designed to 
use a disposable cartridge in the 
synthesis process, allowing multiple back-
to-back production runs for 18F-FDG, the 
most widely utilized PET tracer. The result 
is yield around 65 % (n.d.c.) with little 
maintenance, which is perfect for high-
output FDG production as well as in-
house production laboratories. Integrated diagnostics allow you to measure and record 
minute variables, not only ensuring consistent tracer production, but making GMP 
guidelines easy to meet. The TRACERlab MX FDG module features a Programmable 
Logic Controller (PLC) with an operation program that facilitates user interaction. The 
production process itself is designed to optimize production parameters.  
          
Figure 9: Hardware of an Mx TRACERlab with a disposable 18F-FDG cassettes and reagents assembled 
(G.E.m.s) 
 25 
The standard disposable cassette, assembled for synthesizing 18F-FDG (fig 10)  was 
adapted for fully automated 18FECH synthesis. All the cartridges were removed and the 
orizontal tC-18 cartridge between block 2 and 3 was replaced by a silicon tubing. The 3 ml 
NaOH solution syringe in position 10 was replaced with a plastic plug as this manifold is 
not necessary for this sequence. A receiving cone and a QMA cartridge, for recovery and 
[18F-] elution, respectively, were placed in position 2 and a vial containing 3 ml acetonitrile 
for azeotropic distillation was put in position 3. The precursors, diOTsEt and DMAE, were 
both dissolved in 1 ml acetonitrile, 5 minutes before the synthesis start, and the vial was 
positioned in 5. Two vials containing 5 ml ethanol and 5 ml NaCl 0.9% were placed in 
Positions 8 and 9, respectively. Plus-CM (one or two) cartridge/s was/were tightly inserted 
in position 11 and the silicon tubing coming out from the cartridge/s was connected to the 
final vial. The position 12  was occupied by one plus QMA and one plus C-18 cartridge and 
was connected to a 25 ml vented collector vials with a short needle (in-let of the solutions), 
position 13 was connected to the 25 ml vial to through a silicon tubing and a long needle 
(out-let of the solutions). Other position were connected like as the standard FDG 
synthesis. All connection were screwed tightly. A visual comparison of the two set-up is 
shown in figure 10 and 11. The changes between the standard 18F-FDG cassettes and the 
18FECH cassettes are resumed in table 1. 
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Figure 10:  Synoptic of a traditional Mx TRACERlab assembly when 18F-FDG is produced. 
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Figure 11:  Synoptic of the Mx TRACERlab assembly when 18FECH is produced. 
 
 
Table 1: Modification to the standard 18F-FDG cassettes 
 
The standard 18FDG synthesis sequence was modified and fitted for synthesizing 18FECH. 
In particular, the sequence was adapted for reproducing the one-step method developed 
for the FX F-N Tracer Lab and described in the precedent paragraph. The traditional two-
step method would be difficult, if not impossible, to be transferred to the Mx TRACERlab 
disposable cassettes due to the limited number of position where the reagents vials can be 
placed and to the one-way direction of the manifolds. 
The first steps of the program were similar to those used for 18F-FDG synthesis but 
differently from FDG preparation, the step in which the precursors was dissolved in ACN 
was deleted because they were dissolved by the operator manually before starting the 
sequence.  
Position 18F-FDG 18FECH 
3                                 ACN (7 ml)                                     ACN (3 ml) 
 
5                              Mannose Triflate                   diOTsEt + DMAE in ACN 
 
8                                 EtOH (5 ml)                                  EtOH (5 ml) 
 
9                               Buffer solution                            0.9 % NaCl solution 
 
10                            2 N NaOH Syringe                              Capped 
 
11                         Sep-Pak plus N Allumina            1 or 2 Sep-Pak plus CM 
 
12                           Sep-Pak plus tC18                Sep-Paks plus C18 and QMA 
 
13                       Connected to plus tC18            Connected to a collect vessel 
 
 28 
The [18F]-fluoride production were carried out as described above and the 18F-Fluoride 
solution was transferred to the Mx TRACERlab through a PEEF tubing. Then, it was 
trapped 
on a light-QMA cartridge and eluted to the reactor by a mixture of K2CO3/ K2.2.2 in a 1:1 
solution of acetonitrile/water. The [18F]-fluoride was dried by azeotropic distillation at 95°C 
using three successive additions of acetonitrile (0.7 ml). A solution of di(OTs)Et (25 mg, 70 
nmol) and 100 µl of DMAE (1.0 mmol) in dry acetonitrile (1 ml) was added to the dried 
residue. The reactor was then heated at 120°C for 1 0 minutes and then tempered to 
around 50°C in order to contemporary perform both t he addition and N-alkylation 
reactions. The reaction mixture was purified by passing through a plus C18 cartridge and 
plus-QMA cartridge in position 12 and collected into the 25 ml vial. The reactor and the 
cartridges was rinsed with 15 ml of water and the washing was collected into the same 25 
ml vial. After the first purification the 18FECH solution was withdrawn with the 30 ml right 
syringe in position 14 and passed through one or two plus-CM cartridges (position 11). 
18FECH was retained in the cartridges while the crude solution was collected in a waste 
bottle positioned inside the manipulation hood. The collect vial and the cartridges was 
washed with 5 ml of EtOH and 20 ml of water and 18FECH was then eluted with 5 ml of 
0.9% NaCl solution. The 18FECH solution was gathered in the final vessel by manually 
switching the waste bottle with a sterile vial. The preparation was diluted with 11 ml water. 
Total synthesis time was about  35 min. 
As many different precursors were used in precedent studies (72-75, 78-80) and 
encouraging results were obtained, the feasibility of this labelling reaction with the Mx 
TRACERlab using BrOTsEt, diBrEt and diONosEt, was also investigated and whose RCY 
was compared with RCY using diOTsEt. 
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Table 2: 18FECH synthesis sequence 
 
3.2.3.3. Cartridges activation: 
All the sep-pak described in any approach of this study were treated as follow: plus QMA 
cartridges were activated with 10 ml 0.05 M NaOH solution and subsequently rinsed with 
10 ml water. Plus C-18 cartridges were washed with 10 ml of ethanol and 10 ml of water. 
The CM cartridges were activated by using 5 ml 0.9 % NaCl water solution and rinsed with 
20 ml water.  
The 0.9% NaCl solution was used for eliminating the K+ counterions from the solid phase 
of the cartridges. In fact, the presence of K+ cations in the final solution interferes with the 
DMAE detection by HPLC (vide infra). In the UHPLC methods this problem was avoided 
Step Action 
A                                 18F-Fluoride trapping in the QMA cartridge 
 
B                             18F-Fluoride elution to the reactor by Kry 2.2.2 mixture 
 
C                                               Azeotropic evaporation 
 
D                              Addition of the precursors solution in the reactor vial 
 
E                            Template reaction of the precursors and 18F-Fluoride 
 
F                                                   Cooling of the reaction 
 
G                               Purification between sep-pak plus C-18 and QMA 
 
H                                     Washing the sep-paks and the reactor 
 
I                                   Trapping the 18FECH in 1 ore 2 Sep-Pak plus CM 
 
J                  Washing the CM and the collect vessel with 5 ml EtOH + 10 ml water 
 
K                                  Elution of the 18FECH with 5 ml 0.9 % NaCl 
 
L                                        Dilution of the final solution in water                                   
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but the activation was performed in same way to minimize the presence of K+ in the 
preparations. 
 
3.2.4. Quality controls. 
3.2.4.1. Radiochemical and Chemical Purity: 
An HPLC or UHPLC systems were equipped with an Ion Pac CS 14 column (Dionex, 
Milan, Italy) or a IC-PakTM Cation M/D column (Waters, Milan Italy), respectively, and 
three different detectors in series were used to assess the chemical as well as the 
radiochemical purity of the preparations (radiochemical, electrochemical and UV 
detectors). The analyses were performed with an aqueous solution containing 2 mM 
H2SO4, 2 mM CH3HSO3 and 12.5 % (v/v) acetonitrile as eluent, at the flow rate of 1 ml/min 
for both HPLC or UHPLC system.  
The systems were calibrated by injecting not radioactive standard solutions of the most 
probable by-product and reagent (DMAE, diMMCl, FECH, K+, o-Tosilate) at varying 
concentrations (10, 50, 100, 200 ppm) in order to identify the peaks produced by the 
detectors (Electrochemical and UV). The identification of the 18FECH peak produced by 
the radio-detector was obtained by co-injecting a not radioactive FECH standard 100 ppm.  
As expected the UHPLC system show best separation properties probably due to the best 
mechanical features.  
Radiochemical purity (RCP) was also assessed by TLC using a MeOH/ammonium acetate 
1 M solution 50/50 (v/v) as eluent and silica gel plates 60 F254 as stationary phase.  
 
3.2.4.2. Solvents: 
The concentration of volatile products such as EtOH and ACN or TBA (when used) and 
DMAE in the final solution was assessed by GC with an RTX-1301 column and a FID 
detector.  
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3.2.4.3. Others: 
The sterility and the presence of bacterial endotoxin were tested on different preparations 
by following the European Pharmacopeia guidelines. 
The presence of Kryptofix. 222, when used, was assessed by methods described in the 
European Pharmacopeia for FDG preparations. As a negative control for the assay, a 
18FECH solution prepared by using TBA as phase transfer catalyst was used. 
 
3.2.4.4. Stability of the reagents solution: 
When the synthesis was performed with the Mx TRACERlab, the sequence needs the 
contemporary pre-dissolution of diOtsEt and DMAE in acetonitrile, thus an additional 
analysis was performed on the reagent mixture in order to check the stability of the 
solution of the reagent over time. 20 mg of diOTsEt and 0.1 ml of DMAE were dissolved in 
1 ml of d-ACN. The solution was stored overnight at RT and then an 1H NMR analysis at 
25°C was performed. Subsequently, the NMR tubing wa s heated to 80°C directly inside 
the NMR magnet chamber and a further analysis was performed. 1H NMR analyses of a 
0.1 ml DMAE in 1ml d-ACN solution and of a 20 mg diOTsEt in 1 ml d-ACN solution were 
also carried out  for comparison.   
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4. RESULTS AND DISCUSSION: 
 
 
4.1. RADIOPHARMACEUTICAL SYNTHESIS: 
 
In this dissertation, synthesis of 18F-FECH was carried out by means of different 
synthesizers and by using varying approaches. In the following sessions, the results of the 
trials will be summarized and discussed trying to underline the feasibility and reliability of 
the different approach in term of radiochemical yield but also of radiochemical purity. Final 
aim of this dissertation is to ensure a 18FECH supply for clinical trials. 
 
4.1.1. Automated synthesis (two step reaction) using FX F-N synthesizer: 
 
When the synthesis was performed by using SPE as purification method, 18FECH was 
synthesized in the best conditions in 55 min with a RCY of 43±3% or 32±4% (not corrected 
for decay) depending on if TBA or Kry 2.2.2 were used, respectively. Conversely, when the 
purification was performed by using a semipreparative HPLC, the synthesis time was 65 
min and the yields dropped to 31±3% and 20 ±2%, respectively, in the best conditions. 
 As shown in Fig. 12, the RCY of the reaction was strictly dependent on the reagents 
amounts, and the best results were obtained when 15 mg diOTsEt and 0.03 ml DMEA 
were reacted.  
 33 
 
 34 
Figure 12: (A) Dependence of the 18FECH radiochemical yield on the diOTsEt amount in the two-step 
reaction (n=3). (B) Dependence of the 18FECH radiochemical yield on the DMAE amount in the two-step 
reaction (n=3). (C) Dependence of the 18FECH radiochemical yield on the ACN volume dissolving DMAE in 
the two-step reaction (n=3). ( --- ) Kry 2.2.2 or (—) TBA 
 
While comparable results were achieved when diOTsEt was dissolved in an ACN volume 
ranging between 0.5 and 1 ml, thus indicating a low dependence of the nucleophilic 
substitution step on the solvent volume, ACN amount strongly influenced the alkylation 
step. In fact, as shown in Fig. 12, the RCY dropped drastically when more than 0.4 ml 
ACN were used to dissolve DMAE, while best conditions were obtained with 0.3 ml. A 
possible explanation of this findings is that the alkylation step was obtained at higher 
temperature than the ACN boiling point, so it is necessary to evaporate all the ACN 
amounts to start the reaction between the labelled precursor (18FOTsEt)  previously 
formed and DMAE. In such case DMAE would be both reagent and solvent of the reaction 
at the same time. This thesis is supported also to the fact that in other studies (71) the 
alkylation reaction was performed in neat DMAE without the presence of solvent, in this 
dissertation the use of ACN was preferred for transferring the DMAE in the synthesizer 
reactor due to the really low amount of DMAE used.    
Also the use of the phase transfer catalysts and different purification methods influenced 
the RCY remarkably. When Kry 2.2.2 was employed, less than 10% RCY respect to TBA 
was obtained regardless of the purification method. The possible competition of the amino-
polyether ternary amine with the DMAE in the alkylation reaction can reasonable explain 
the lower RCY. 
 
4.1.2. Automated synthesis (one-step reaction) using FX F-N synthesizer. 
When the one-step reaction was adopted, as both the reagent were mixed in the same vial 
and solved with ACN, the solvent volume greatly influenced the RCY. Namely, a 
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considerable decrease was observed when the total reaction volume was more than 0.5 
ml (Fig. 13) while the best result was obtained when the total reaction volume was 0.4 ml. 
 
Figure 13. Dependence of the 18FECH radiochemical yield on the total ACN volume in the one-step reaction 
(n=3). 
 
With respect to the dependence of the reagents amounts on the RCY instead, the one-
step reaction showed a similar trend to the two step one (data not shown) but best result 
was achieved with 12 mg diOTsEt and 0.03 ml DMAE, respectively. 
18FECH synthesis was carried out using only TBA as activator and SPE as purification 
method, as this condition showed the better results in the two-step method trial. A  48±1% 
RCY in 43 min was obtained (not corrected for decay) demonstrating the reliability and 
feasibility of the approach.  
In fact, despite the presence of a large molar excess of the DMAE in the reaction mixture 
compared to [18F]-fluoride, the18FEtOTs formation did not seem to be affected by the 
competition between [18F]-fluoride and DMAE in the nucleophilic substitution. This result 
leads to the reasonable conclusion that the formation of 18FEtOTs intermediate is 
 36 
kinetically favoured with respect to other by-products such as diMM+ that are derived from 
a direct reaction between DMAE and di(oTs)Et. In the present study, the simultaneous 
presence of the reagents in the reaction mixture brought to 18FECH formation anyway. 
This findings are in agreement with the results published in (78) were, at these reaction 
conditions, was found that the displacement of the –OSulfonate (-OTf, -OTs) group by the 
18F-fluoride take place also in presence of competing amines.    
As summarized in Table 3 where all the approaches described so far are shown; the one-
step method showed superior features with respect to the two-step approach in terms of 
RCY, synthesis time and feasibility, although both of them were comparable in term of 
chemical and radiochemical purity. 
 
 
Table 3: Summary of the approaches performed with the FX F-N Tracer Lab in the best conditions of 
reagents amounts (15 mg of diOTsEt and 0.03 ml of DMAE) 
  
Moreover, the proof of concept of feasibility of  the one-step approach can support the 
application of this method also to the preparation of other radiopharmaceuticals, such as 
18F-Fluoroethyltyrosine (18FET), whose synthesis involves firstly the traditional preparation 
of the 18F-Fluoro alkylating agent and then, the reaction with a second  substrate. 
Approach Duration Purification by  
2 steps                  HPLC                      65 min.             TBA                 47       31   
 
2 steps                  HPLC                      65 min.             Kry 2.2.2          30       20  
 
2 steps                  SPE                        55 min.              TBA                 60       43  
 
2 steps                  SPE                        55 min.              Kry 2.2.2          45       32 
 
1 step                    SPE                        43 min.              TBA                 62       48   
 
      RCY % 
(d.c. / n.d.c.) Catalyst 
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Secondly, this method can more easily be subjected to automation and can more easily be 
transferred to other synthesizers with minor arrangement, as described hereafter for the 
Mx TRACERlab. Differently from reported in (80) both the approaches described herein, 
suggested that the purification of 18FEtOTs intermediate is not mandatory in order to 
achieve high RCY and RCP, if a sufficient amount of di(OTs)Et was used in the reaction. 
 
 
4.1.3. Automated synthesis (one-step reaction) with Mx TRACERlab: 
It is worth to notice that the Mx TRACERlab platform is not able to support a traditional 
two-steps approach. This is manly due to the synthesizer and hardware cassettes body 
where only one position in the first cassette block is available for the insertion of a reagent 
vial. In the same way, in a traditional Mx TRACERlab is not possible to perform a 
preparative HPLC purifications of the products. In opposition, the one-step method can be 
easily performed by applying some modification to the standard 18FDG cassettes and the 
SPE purification can be used. Thus, the procedure was studied in order to reply the steps 
followed by the FX F-N Tracer Lab and for this reason an additional 25 ml collect vessel 
had to be added to the assembly.   
Moreover, the Mx TRACERlab approach was tested by using different symmetric or 
asymmetric O-sulfonates precursors trying to improve the RCY respect to the diOTsEt 
used in the FX F-N approaches. The results obtained are resumed in table 4. 
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Table 4: Summary of the results obtained using different precursors with the Mx TRACERlab.  
* syntheses failed because hot ACO dissolve the cassette body.  
** Synthesis failed because all the activity evaporate from the reactor. 
 
As reported, when this approach was applied using the Mx TRACERlab, best results were 
obtained by using diOtsEt, with a RCY of 17±2 % and 10±1 (not decay corrected) in 35 
min, if two or one plus CM were used, respectively. The lower yield compared to the same 
approach using the FX F-N Tracer Lab can be addressed to the following reasons: i) FX F-
N use a fixed glassy carbon reactor with a conical bottom and with a deep assessment of 
temperature and pressure. On the other hand, the Mx TRACERlab owns a disposable 
glass reactor with a flat bottom and without the possibility to low the temperature of the 
reaction mixture if not by switching of the heater and waiting for some minutes ii) liquid 
movement through the Mx TRACERlab cassettes is dependent by the direction of the 
manifolds and all the manifold (excepted position 2) are two-way. This imply that some 
transferring of the liquid (reagent or product) have to follow longer and more complicated 
path. iii) in some steps, the liquid flow through the cassettes, has to be regulated by two 30 
ml syringes withdrawn or pushing. In this cases the flow is quite high a this can cause 
some product loss during the SPE purification steps with CM cartridge/s. Anyway, the RCY 
Precursor nmol/mg # CM 
diOTsEt               0.07 / 25                  ACN                          1                10 +/- 1 % 
 
diOTsEt               0.07 / 25                  ACN                          2                17 +/- 2 % 
 
diONosEt            0.07 / 30                   ACO                          2                 0 % * 
 
BrOTsEt             0.07 / 20                   ACN                           2               11 +/- 1 % 
 
diBrEt                  0.07 / 13                  ACN                           2                 0 %  **      
 
Solvent 
(ml) 
        RCY (n.d.c) 
(n.d.c.) 
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obtained using two plus-CM cartridge is comparable to that obtained in the preparation of 
18FMCH as reported in (81) with the same synthesizer.  
Regarding the other O-Sulfonates precursors,  a lower RCY (11 %) was obtained by using 
BrOTsEt instead of the symmetrical diOTsEt while complete failure was obtained with 
diNosEt and diBrEt. For BrOTsEt, we suppose that the reaction temperature should be 
firstly decreased in order to allow  the substitution of the –OTs group with formation of 
18FBrEt but avoiding the evaporation of the intermediate, and then increased for allowing 
the substitution of the –Br atom. 
Concerning diONsEt, we found that it is not soluble in ACN so the reaction has to be 
performed in ACO. However hot ACO is not suitable for the cassettes body and it was not 
possible to extract the reaction mixture from the reactor. 
When diBrEt was used, we notice a complete loss of the radioactivity during the reaction 
probably due to the high volatility of the precursor and of the 18F-Fluorinated intermediate. 
Also in this case, improved reaction conditions should be found and set.   
It is worth to say that, using the Mx TRACERlab, the choice of the correct amounts of 
reagents (O-Sulfonate precursors, DMAE and ACN) is critical, above all for avoiding the 
clogging of the cassettes tubing and cartridge due to the precipitation of un-reacted O-
sulfonates when the reaction is diluted with water and the reactor is rinsed. 
 
4.2. QUALITY CONTROLS: 
 
The synthesis of 18FECH is a reaction involving complex interaction between three 
precursors such as [18F]-Fluoride, diOTsEt and DMAE, as well as ancillary substances 
such as solvent (ACN) and phase transfer catalysts (TBA and Kry 2.2.2).  
It is worth to notice that DMAE has two possible groups that can act as nucleophilic agents 
in the reaction with diOtsEt precursor or with 18FOTsEt intermediate synthon (namely the 
amino and the hydroxyl group), this fact may potentially bring to the formation of different 
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and unexpected by-products both radioactive and un-radioactive. In addition, the presence 
of un-reacted 18F-Fluoride and of 18FOtsEt has to be assessed as radioactive 
contaminants. In figure 14 are resumed the radioactive products that may form during this 
reaction. 
 
                 
OTsOTs
N
OH
N
+ OH
F18 N
O F18
F18
F18OTs
+
DMAE
bis(OTs)Et
+
18FOTsEt
18F-fluoride
18FECH
1
 
Figure 14: Potential 18F-labelled products formed by reacting diOTSEt, 18F-fluoride and DMAE.  
 
Furthermore, due to the high excess of cold precursors compared to 18F-Fluoride, double 
reactions between the precursors themselves have also to be taken in account and these 
kind of reactions would bring to not radioactive by-products. All these considerations may 
result in the formation of varying by-products and also to the presence of partially reacted 
precursors, such as O-Tosylated products. In figure 15 all the possible theoretical 
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reactions between precursors are resumed and the possible not radioactive products are 
shown. 
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 Figure 15: Potential not radioactive by-product formed by reacting diOTsEt and DMAE  
 
For this reasons and in spite of the purification methods of choice, reliable quality controls 
must be designed and accomplished in order to assess the presence of all the possible by-
products. In this study, three different chromatographic systems were adopted in order to 
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analyze the reaction mixtures and the final product. Due to the nature of the varying 
substances detected, both the HPLC and UHPLC systems are equipped with three 
detector in series. 
 
4.2.1. Comparison between the synthesis and purification methods: 
In table 5 are resumed the results obtained in the quality controls of the preparations 
performed with the two different approaches (one or two-step), the two purification 
methods (HPLC and SPE) and the two synthesizers (FX F-N and Mx).  
 
 
Table 5: Summary of the quality controls performed by UPLC on the preparation carried out with the two 
synthesizers, the two approaches and the two purification methods.  
ND: under limit of detection 
 
4.2.2. Radiochemical purity: 
[18F]-Fluoride, 18FEtOTs and 18FECH were evaluated by means of radiometric detection 
and, in the HPLC system, have a retention time of 2.5, 5.6 and 8.0 min, respectively.  
In UHPLC system, a rapid and better separation could be obtained and the following 
retention times were found: [18F]-Fluoride = 2.0, 18FEtOTs = 3.2 and 18FECH = 4.05.  
Approach / 
Synthesizer 
K+ 
Purification 
2 steps / FX F-N     HPLC         10        ND         38         106               ND            ND           99      
 
2 steps / FX F-N     SPE            11       ND         38          107               ND           ND           99 
 
1 steps / FX F-N     SPE            10       ND         37           95                ND           ND           99     
 
1 steps / Mx           SPE           280      230        54           70              present       ND           99 
 
RCP % FECH DMAE DMM+ UV by-prod OTs- 
Conductometer UV Radio 
 43 
The identity of 18FECH was verified on conductimetric detector by injecting the cold FECH 
standard as shown in figure 16. 
 
Figure 16: UPLC Chromatograms of a 18FECH preparation on the radiometric detector (red) and a 100 ppm 
standard of cold-FECH on conductometer detector (black).  
 
In figure 17 is shown a typical chromatogram obtained by injecting a bulk solution just after 
the SPE purification through the C-18 and QMA cartridge or a preparative HPLC 
purification, in spite of the approach used (one-step or two-steps) and in spite of the 
synthesizer used (FX F-N or Mx TRACERlab). In all the case the radiochemical purity is 
comparable and it is evident that it is not sufficient for an injectable product.  
On other hands, as shown by the comparison between figure 17 and figure 18, the last 
filtration through the CM cartridge/s have a strong influence on the radiochemical purity 
and can be considered the most important step of the purification. 
 
FECH 
18FECH 
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Figure 17 : Typical chromatogram (radiodetector) of the crude mixture before the CM purification in spite of 
the approach or of the synthesizer used.  
 
 
Figure 18 : Typical chromatogram (radiodetector) of the final solutions after the CM purification in spite of 
the approach or of the synthesizer used. 
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Regardless of the different synthetic approaches, the radiochemical purities of the 18FECH 
solutions at the end of synthesis were comparable and were greater than 99 %. As an 
example, the comparison between the chromatograms obtained by a two steps/HPLC 
purification/FX F-N and a one step/SPE/Mx TRACERlab approach can be observed in 
figure 19. 
 
 
Figure 19: Comparison between two typical chromatograms (radio-detector) obtained from a 18FECH 
preparation by a two steps/HPLC purification/FX F-N approach (A) and a one step/SPE/Mx TRACERlab 
approach (B). 
 
Radiochemical purity (RCP) was also assessed by radio-TLC and the following retention 
times were obtained: [18F]-fluoride: Rf=0.1 18FECH Rf=0.8, respectively. 
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4.2.3. Chemical purity: 
In spite of the theoretic possibility to form the by-product illustrated in figure 15, the setting 
of the HPLC and UPLC analyses and the identification of the chromatographic peak are 
dependent to the commercial availability of the standards. Products a1, a2, b1, b2, b3 in 
figure 15 are not commercially available so it was not be possible to determine their 
presence in the final solution. On the other hand, a calibration curve was fitted for the 
following standards: K+, DMAE, FECH and dMM+ (product c1 in figure 15) by using the 
conductimetric detector. 
HPLC system is able to separate Na+, DMAE and diMM+ but K+ co-elutes with DMAE and 
the relative quantification of these products is difficult. DMAE (and K+) and diMM+ have a 
retention times (Rt) of 6.1 and 10.2 min, respectively. 
In the UHPLC methods all the product are well separated and quantified. In the UHPLC 
system the following Rt were found: K+ = 2.5 min. DMAE = 3.1 min. cold-FECH = 4.2 min. 
diMM+ = 5.4 min. The chromatogram of the standard and the calibration curves are shown 
in figure 20 and 21, respectively. 
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Figure 20: UPLC Chromatogram on the conductometer detector of the 100 ppm standard solutions  
 
 
Figure 21: Calibration curves and correlation coefficients for K+, DMAE, FECH and dMM+ standard 
soltutions. 
 
As reported in table 5, the chemical purity of the final solution is quite influenced by the 
approach used. In spite of the synthetic approach (one-step or two-steps) or of the 
synthesizer used for the synthesis, the formation of diMM+, a cationic by-product formed 
DMAE 
K+ 
DMM+ 
FECH 
K+       R2 = 0.989  DMAE       R2 = 0.978  
dMM+       R2 = 0.989  FECH       R2 = 0.985  
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by the direct reaction of diOTsEt with DMAE followed by an intra-molecular cyclization, 
was found. The proposed mechanism of dMM+ formation is showed in figure 22. 
 
       
Figure 22. Proposed mechanism of dMM+ formation.  
 
 To the best of our knowledge, the presence of diMM+ in 18FECH solutions was not 
described so far and its identity was confirmed by comparison with the commercial 
standard in the same HPLC or UHPLC conditions. As far as we know, toxicological data 
about diMM+ in human beings were not reported so far, since the only studies published 
are related to plants growth. In the set of reactions performed in this dissertation, diMM+ 
was detected in a concentration ranging between 41 and 179 mg/l regardless of the 
purification method. As reported in table 5 the mean concentration found when the Mx 
TRACERlab was used is lower than the one found in the other approaches. It is difficult to 
give a reason of this behaviour but it is supposed that the presence of two CM cartridge 
positively influence the retention of this compound, blocking the dMM+ in the CM and thus 
limiting its amount in the final solution. 
 
Differently from dMM+, the amount of DMAE and K+ is really low (under limit of detection 
and ca. 10 ppm, respectively) when the syntheses are performed with the FX F-N tracer 
lab, in spite of the purification method and approach. Indeed, when the Mx TRACERlab is 
used, the DMAE and K+ amount rise to 230 and 280 ppm, respectively. These results may 
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indicate that the presence of the two CM cartridge has a negative impact on the 
elimination of this two substances from the final solution.  
The toxicity of DMAE is not especially concerning since its use is documented as an active 
substance in dermal creams and treatment of mental impairment (71). However, 
increasing amounts of DMAE were showed to reduce the uptake of 18FECH in prostate 
cancer cells in vitro (82,83), even if its inhibitory effect has not been yet clarified (60). 
Therefore, in order to avoid any physiological competition, the DMAE concentration in the 
final 18FECH radiopharmaceutical solution should be limited. 
As reported before,  if K+ cation is present in the final solution, the presence of DMAE was 
not appraisable in the HPLC method, as DMAE co-elutes with K+ cations. The source of K+ 
is normally the Kry 2.2.2./K2CO3 solution when it is used as transfer phase catalyst but it 
was also found the presence of a large amount of K+ in the un-treated CM cartridges.   The 
issue was solved by varying approach that allow the perfect separation and determination 
of DMAE amount: 
i) differently from reported in other study (81), plus CM cartridges were activated 
with 0.9% NaCl water solution. We experienced that the use of NaCl both 
decrease the presence of K+ inside the filters due to the K+ substitution with Na+ 
and positively acts on the 18FECH retention in the CM cartridge, increasing the 
RCY during the synthesis. 
ii) The UHPLC methods reported before, was developed. It is able to perfectly 
separate and give a quantification of DMAE and K+ 
iii) DMAE amount was also checked with GC analysis (vide infra) 
 
In our opinion, the possible co-elution of this two substances could explain the high 
variability in the DMAE concentrations in the synthesis of [18F]-fluorinated choline 
 50 
analogues reported so far (65, 71, 72, 81, 84). In all this cases DMAE amount was 
assessed by HPLC analysis only.  
A comparison between the chromatograms obtained by a two steps/HPLC purification/FX 
F-N and a one step/SPE/Mx TRACERlab approach can be observed in figure 23. 
 
 
Figure 23: Comparison between two typical chromatograms (conductimeter-detector) obtained from a 
18FECH preparation by a two steps/HPLC purification/FX F-N approach (A) and a one step/SPE/Mx 
TRACERlab approach (B). 
 
The presence of any UV-absorbing impurities, such as free OTs− anions and tosylated by-
products, was proved by UV detection at 206 nm. With the exception of the synthesis 
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performed with Mx TRACERlab where the presence of tosylated product were detected, 
no UV-absorbing products were found.  A comparison between the chromatograms 
obtained by a two steps/HPLC purification/FX F-N and a one step/SPE/Mx TRACERlab 
approach can be observed in figure 24. 
 
 
Figure 24: Comparison between two typical chromatograms (UV detector) obtained from a 18FECH 
preparation by a two steps/HPLC purification/FX F-N approach (A) and a one step/SPE/Mx TRACERlab 
approach (B). 
 
 
 
A 
B 
O-Tosilate by-product ?  
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4.2.4. Solvents: 
During the experiments, DMAE amount was also evaluated by means of GC analysis and 
the experimental setup for detecting DMAE together with TBA, ACN and EtOH in an 
unique run was developed. The mean concentrations of the latter three reagents were 115 
mg/L, 192 mg/L and 117 mg/l, respectively; while the concentration of DMAE was around 
0.5 mg/l. In general, a good agreement between the results obtained by UHPLC and GC 
analyses was accomplished. EtOH, ACN, TBA (when used) and DMAE in the final 
solutions exhibit the following retention times:  Rt=2.6, 3.1, 4.5 and 6.1 min, respectively. 
 
4.2.5. Others:  
Both the 18FECH preparation synthesized by using TBA or Kry 2.2.2. showed a visible spot 
when tested with the colorimetric method described in (85) and reported in Pharmacopeia 
for 18F-FDG preparation. Probably, due to the presence of DMAE as an impurity in the final 
solutions, it was not possible to evaluate the concentration of Kry 2.2.2 by means of the 
colorimetric spot test reported in (85). This method appears not specific for Kry 2.2.2 but it 
is sensitive to any tertiary amine present in solution and gives false positive results if used 
for testing 18FECH preparations. 
All the tested samples were sterile and bacterial endotoxin free ( < 0.5 EU/ml). 
 
4.2.6. Stability of the reagents solution: 
The feasibility of the 18FECH synthesis with Mx Tacer Lab is dependent on the stability of 
the reagent precursors in a ACN solution as diOTsEt and DMAE were pre-dissolved into 
the vial in position 5 of the cassette. The stability of a ACN solution containing both the 
diOTsEt and DMAE reagents was assessed by 1H NMR at two different temperature (25°C 
and 80°C). The spectra of the mixture were compared  with the single spectra of the two 
precursors. All 1H NMR spectra are gathered in figure 25. 
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Figure 25: Comparison between the NMR spectra obtained by: 20 mg of diOTsEt dissolved in 1 ml of ACN 
(A) 0.1 ml of DMAE dissolved in 1 ml of ACN (B) a solution obtained by dissolving 20 mg of diOtsEt and 0.1 
C  
x  x  x  o  o  o  o  
D  
x  x  o  o  o  o  ?  ?  ?  
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ml of DMAE in 1 ml of ACN at RT (C) a solution obtained by dissolving 20 mg of diOtsEt and 0.1 ml of DMAE 
in 1 ml of ACN heated at 80°C ( D)   
o = signal assigned to diOTsEt  x = signals assigned to DMAE  ? = new unknown signals (new products) 
 
diOTsEt (Fig.25 A)  1H NMR (d-ACN, 300 MHz) δH ppm: 2.42 (s, 6H, -CH3), 4.20 (s, 4H, -
CH2), 7.45 (d, 4H, -CH), 7.72 (d, 4H, -CH). 
DMAE (Fig.25 B)  1H NMR (d-ACN, 300 MHz) δH ppm: 2.13 (s, 6H, -CH3), 2.29 (t, 2H, -
CH2), 3.45 (t, 2H, -CH2), 4.31 (s, 1H, -OH). 
 
As showed in the panels of figure 25,  the 1H NMR of the mixture, acquired at 25°C, is 
equivalent at the sum of the two spectra of the single reagents. This means that no 
reaction between the reagents has happened after 24 h at RT. Conversely, in the 1H NMR 
of the mixture acquired at 80°C, it is possible to notice the presence of new peaks 
indicating the starting of a reaction between DMAE and diOTsEt with subsequent 
formation of new products. In conclusion, the reagents mixture appears to be stable at RT 
and thus the reagent can be pre-solved and mixed up to 24 hours before starting the 
synthesis without influencing the yield of the reaction.  
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5. CONCLUSIONS: 
 
The use of 18FECH radiopharmaceutical in Nuclear Medicine departments is dramatically 
increasing due the possibility to give diagnostic information in fields where the traditional 
PET/CT imaging with 18FDG is not useful, such as, mainly in prostate and brain cancer. 
The metabolic pathway followed by 18F-labelled choline analogue allows to detect cancer 
cells showing uncontrolled growth and enhanced synthesis of phospholipid membranes.  
In this dissertation a deep examination of the possible ways to produce 18FECH were 
accomplished and the use of two different commercial automatic synthesizers, purification 
and synthetic approaches were  evaluated. As the final aim of this discussion is to obtain a 
reliable synthetic way of a radiopharmaceutical for human use, particular attention was 
paid to develop a sure set of quality controls. 
18FECH synthesis was carried out with a FX F-N Tracer Lab obtaining medium or high 
RCY and high purity in every conditions. However, the needing of compliance to the 
European Pharmacopeia, strongly suggests the choice of an automatic synthesizers able 
to operate by using disposable device. For this reason, the one-step synthetic path was 
transferred to Mx TRACERlab. 
Synthesis of 18FECH with the Mx TRACERlab is also possible by using diOtEt as a 
precursor, but with a lower RCY. Anyway, the RCY is comparable to that obtained for 
commercial 18FMCH with the same synthesizer, as already reported in literature and, if 
produced in a large scale, appears to be sufficient for a 18FECH supply for a daily activity 
of a Nuclear Medicine facility. Concerning the use of other precursors, further studies are 
necessary, probably changing the reaction parameters such as reaction temperature and 
time. 
The greatest concern by using the Mx TRACERlab synthesizer is about the chemical 
purity of the product that was little lower than the radiotracer produced by the FX F-N 
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Tracer Lab since still traces of DMAE, K+ and O-Tosylate by-products were found in the 
18FECH preparations. On this topic too, further studies are ongoing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
6. REFERENCES: 
 
 
1. Blusztajn JK. Developmental neuroscience: enhanced choline, a vital amine. Science 
281:794–795, 1998. 
2. Sheard NF, Zeisel SH. Choline: an essential dietary nutrient? Nutrition 5:1–5, 1989. 
3. Sweet DH, Miller DS, Pritchard JB. Ventricular choline transport—a role for organic 
cation transporter 2 expressed in choroids plexus. J Biol Chem 276:41611–416119, 2001. 
4. Zeisel SH, da Costa KA, Franklin PD, Alexander EA, Lamont JT, Sheard NF, Beiser A. 
Choline: an essential nutrient for humans. FASEB J 5:2093–2098, 1991. 
5. Zeisel SH. Choline: essential for brain development and function. Adv Pediatr 44:263–
295, 1997. 
6. Zeisel SH, Blusztajn JK. Choline and human nutrition. Annu Rev Nutr 14:269–296, 
1994. 
7. Fisher MC, Zeisel SH, Mar MH, Sadler TW. Inhibitors of choline uptake and metabolism 
cause developmental abnormalities in neurulating mouse embryos. Teratology 64:114–
122, 2001. 
8. Blusztajn JK, Wurtman RJ. Choline and cholinergic neurons. Science 221:614–620, 
1983. 
9. Wessler I, Kilbinger H, Bittenger F, Kirkpatrick CJ. The biological role of non-neuronal 
acetylcholine in plants and humans. J Pharmacol 85:2–10, 2001. 
10. Wessler I, Kirkpatrick CJ, Racke´ K. Non-neuronal acetylcholine, a locally acting 
molecule, widely distributed in biological systems: expression and function in humans. 
Pharmacol Ther 77:59–79, 1998. 
11. Michel V, Yuan Z, Ramsubir S, Bakovic M. Choline Transport for Phospholipid 
Synthesis. Exp Biol Med 231:490–504, 2006 
 59 
12. Kent C. Regulatory enzymes of phosphatidylcholine biosynthesis: a personal 
perspective. Biochim Biophys Acta 1733:53–66, 2005. 
13. Aoyama C, Liao H, Ishidate K Structure and function of choline kinase isoforms in 
mammalian cells. Prog Lipid Res 43:266–281, 2004. 
14. McMaster CR, Bell RM. CDP-choline:1,2-diacylglycerolcholinephospho- transferase. 
Biochim Biophys Acta 1348:100–110, 1997. 
15. Vance JE, Vance DE. Metabolic insights into phospholipids function using gene-
targeted mice. J Biol Chem 280:10877–10880, 2005. 
16. Jackowski S, Fagone P. CTP:phosphocholine cytidylyltransferase: paving the way 
from gene to membrane. J Biol Chem 280:853–856, 2005. 
17. Bakovic M, Waite K, Tang W, Tabas I, Vance DE. Transcriptional activation of the 
murine CTP:phosphocholine cytidylyltransferase gene (Ctpct): combined action of 
upstream stimulatory and inhibitory cis-acting elements. Biochim Biophys Acta 1438:147–
165, 1999. 
18. Golfman LS, Bakovic M, Vance DE. Transcription of the CTP: phosphocholine 
cytidylyltransferase alpha gene is enhanced during the S phase of the cell cycle. J Biol 
Chem 276:43688–43692, 2001. 
19. Bakovic M, Waite K, Vance DE. Oncogenic Ha-Ras transformation modulates the 
transcription of the CTP:phosphocholine cytidylyltransferase alpha gene via p42/44MAPK 
and transcription factor Sp3. J Biol Chem 278:14753–14761, 2003. 
20. Vance DE. Phosphatidylethanolamine N-methyltransferase: unexpected findings from 
curiosity-driven research. Eur J Med Res 1: 182–188, 1996. 
21. Vance DE, Walkey CJ, Cui Z. Phosphatidylethanolamine Nmethyltransferase from 
liver. Biochim Biophys Acta 1348:142–150, 1997. 
 60 
22. Jacobs RL, Stead LM, Devlin C, Tabas I, Brosnan ME, Brosnan JT, Vance DE. 
Physiological regulation of phospholipid methylation alters plasma homocysteine in mice. J 
Biol Chem 280:28299–28305, 2005. 
23.  Fisher AB, Dodia C, Chander A, Kleinzeller A. Transport of choline by plasma 
membrane vesicles from lung-derived epithelial cells. Am J Physiol 263:C1250–C1257, 
1992. 
24. Deves R, Krupker RM. The binding and translocation steps in transport as related to 
substrate structure. A study of choline carrier of erythrocytes. Biochim Biophys Acta 
557:468–485, 1979. 
25. Simon JR, Atweh S, Kuhar MJ. Sodium-dependent, high affinity choline uptake: a 
regulatory step in the synthesis of acetylcholine. J Neurochem 26:909–922, 1976. 
26. Grassl SM. Choline transport in human placental brush-border membrane vesicles. 
Biochim Biophys Acta 1194:203–213, 1994. 
27. Porter RK, Scott JM, Brand MD. Choline transport into rat liver mitochondria. 
Characterization and kinetics of a specific transporter. J Biol Chem 267:14637–14646, 
1992. 
28. Van Rossum GDV, Boyd CAR. Sodium-dependent and –independent choline uptake 
by type II epithelial cells from rat lung. J Membr Biol 162:147–156, 1998. 
29. Singer S, Souza K, and Thilly WG. Pyruvate utilization, phosphocholine and adenosine 
triphosphate (ATP) are markers of human breast tumor progression: A 31P and 13C-nuclear 
magnetic resonance (NMR) spectroscopy study. Cancer Res. 55: 5140-5145, 1995 
30. Ting YT, Sherr D, and Degani H. Variations in the energy and phospholipid metabolism 
in normal and cancer human mammary epithelial cells. Anticancer Res. 16: 1381-1388, 
1996. 
 61 
31. Aboagye EO, and Bhujwalla ZM. Malignant transformation alters membrane choline 
phospholipid metabolism of human mammary epithelial cells. Cancer Res. 59: 80-84, 
1999. 
32. Ackerstaff E, Pflug BR, Nelson JB, and Bhujwalla ZM. Detection of increased choline 
compounds with proton nuclear magnetic resonance spectroscopy subsequent to 
malignant transformation of human prostatic epithelial cells. Cancer Res. 61: 3599-3603, 
2001. 
33. Degani H, Horowitz A and Itzchak Y. Breast tumors: evaluation with 31-P NMR 
spectroscopy. Radiology 161: 53-56, 1986. 
34. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 5: 303-324, 
1992. 
35. Ronen SM. and Leach MO. Imaging biochemistry: applications to breast cancer. 
Breast Cancer Res. 3: 36-40, 2001. 
36. Ratnam S. and Kent C. Early increase in choline kinase activity upon induction of the 
H-ras oncogene in mouse fibroblast cell lines. Arch. Biochem. Biophys. 323: 313-322, 
1995. 
37. Bhakoo KK, Williams SR, Florian CL, Land H, and Noble MD. Immortalization and 
transformation are associated with specific alterations in choline metabolism. Cancer Res. 
56: 4630-4635, 1996. 
38. Ronen SM, Jackson LE, Beloueche M, and Leach MO. Magnetic resonance detects 
changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. 
Br. J. Cancer. 84: 691-696, 2001. 
39. de Molina AR, Banez-Coronel M, GutierrezR, Rodrigez-Gonzalea A, Olemeda D, 
Megais D, Lacal JC. Choline kinase activation is a critical requirment for the proliferation of 
primary human mammary epithelial cells and breast tumors progression, Cancer Res 64: 
6732-9, 2004. 
 62 
40. Hernandez-Alcoceba R, Saniger L, Campos J, Nunez MC, Khaless F, Gallo MA, 
Espinosa A, and Lacal JC. Choline kinase inhibitors as a novel approach for 
antiproliferative drug design. Oncogene. 15: 2289-2301, 1997. 
41. Hernandez-Alcoceba R, Fernandez F, and Lacal JC. In vivo antitumor activity of 
choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res. 59: 
3112-3118, 1999. 
42. de Molina AR, Rodriguez- Gonzalez A, Lacal JC. From ras signaling to ChoK 
inhibitors: a further advance in anticancer drug design, Cancer lett. 206: 181- 91, 2004. 
43. Exton JH. Signaling through phosphatidylcholine breakdown. J. Biol. Chem. 265: 1-4, 
1990. 
44. Pelech S L and Vance DE. Signal transduction via phosphatidylcholine cycles. Trend. 
Biochem. Sci. 14: 28-30, 1989. 
45. Ratnam S, and Kent C, Early increase in choline kinase activity upon induction of the 
H-ras oncogene in mouse fibroblast cell lines. Arch. Biochem. Biophys. 323: 313-322, 
1995. 
46. Jimenez B, del Peso L, Montaner S, Esteve P, and Lacal JC. Generation of 
phosphorylcholine as an essential event in the activation of Raf-1 and MAPkinases in 
growth factors-induced mitogenic stimulation. J. Cell. Biochem. 57: 141-149, 1995. 
47. Nishizuka Y. Intracellular Signaling by Hydrolysis of Phospholipids and Activation of 
Protein Kinase C. Science. 258: 607-614, 1992. 
48. Kiss Z. Regulation of mitogenesis by water-soluble phospholipid intermediates. Cell 
Signal. 11: 149-157, 1999. 
49. Foster DA, lizhong Xu, Phospholipase D in Cell proliferation and cancer Molecular 
Cancer Res 1, 789-800, 2003. 
50. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and 
treatment. Nat Rev Cancer 4(8):604-1, 2004. 
 63 
51. Hara T, Kosaka N, Kishi H: PET imaging of prostate cancer using carbon-11-choline. J 
Nucl Med 39:990-995, 1998 
52. Hara T, Kosaka N, Shinoura N, et al: PET imaging of brain tumor with [methyl-
11C]choline. J Nucl Med 38:842-847, 1997 
53. Yoshida S, Nakagomi K, Goto S, et al: C-choline positron emission tomography in 
bladder cancer: report of four cases. Int J Urol 13:829- 831, 2006 
54. Picchio M, Treiber U, Beer AJ, et al: Value of 11C-choline PET and contrast-enhanced 
CT for staging of bladder cancer: Correlation with histopathologic findings. J Nucl Med 
47:938-944, 2006 
55. Gofrit ON, Mishani E, Orevi M, et al: Contribution of 11C-choline positron emission 
tomography/computerized tomography to preoperative staging of advanced transitional 
cell carcinoma. J Urol 176:940-944, 2006; discussion 944. 
56. Farsad M, Schiavina R, Castellucci P, et al: Detection and localization of prostate 
cancer: Correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J 
Nucl Med 46:1642-1649, 2005 
57. de Jong IJ, Pruim J, Elsinga PH, et al: Visualization of prostate cancer with 11C-choline 
positron emission tomography. Eur Urol 42:18-23, 2002 
58. de Jong IJ, Pruim J, Elsinga PH, et al: Visualisation of bladder cancer using (11)C-
choline PET: First clinical experience. Eur J Nucl Med Mol Imaging 29:1283-1288, 2002 
59. Kotzerke J, Gschwend JE, Neumaier B. PET for prostate cancer imaging: still a 
quandary or the ultimate solution? J Nucl Med 2002;43:200–2. 
60. Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN. Cancer imaging with fluorine-
18-labeled choline derivatives. Semin Nucl Med 2007;37:420–8. 
61. Cimitan M, Bortolus R, Morassut S, et al. [18F]fluorocholine PET/CT imaging for the 
detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive 
patients. Eur J Nucl Med 2006;33:1387–98. 
 64 
62. Deves R, Krupka RM. The binding and translocation steps in transport as related to 
substrate structure: a study of the choline carrier of erythrocytes. Biochim Biophys Acta 
1979;557:469–85. 
63. Clary GL, Tsai CF, Guynn RW. Substrate specificity of choline kinase. Arch Biochem 
Biophys 1987;254:214–21. 
64. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled 
choline as an oncologic tracer for positron emission tomography: initial findings in prostate 
cancer. Cancer Res 2001;61:110–7. 
65. Hara T, Kosaka N, Hiroichi H. Development of 18F-fluoroethylcholine for cancer 
imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 
2001;43:187–99. 
66 Glunde K, Jacobs MA, Bhujwalla ZM: Choline metabolism in cancer: Implications for 
diagnosis and therapy. Expert Rev Mol Diagn 6:821-829, 2006 
67. Yamaguchi T, Lee J, Uemura H, et al: Prostate cancer: A comparative study of 11C-
choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol 
Imaging 32:742-748, 2005 
68. Kwee SA, Coel MN, Lim J, et al: Combined use of F-18 fluorocholine positron emission 
tomography and magnetic resonance spectroscopy for brain tumor evaluation. J 
Neuroimaging 14:285-289, 2004 
69. Padma MV, Adineh M, Pugar K, et al: Functional imaging of a large demyelinating 
lesion. J Clin Neurosci 12:176-178, 2005 
70. Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I. PET with 18F-labelled 
choline-based tracers for tumour imaging: a review of the literature Eur J Nucl Med Mol 
Imaging DOI 10.1007/s00259-010-1496-z 
 65 
71. Pascali G, D'Antonio L, Bovone P, Gerundivi P, August T. Optimization of automated 
large-scale production of [18F]-fluoroethylcholine for PET prostate cancer imaging. Nuc 
Med Biol 2009;36(5): 569-74 
72. Zuhayra M, Alfteimi A, Papp L, et al. Simplified fast and high yielding automated 
synthesis of [18F]fluoroethylcholine for prostate cancer imaging. Bioorg Med Chem 
2008;16:9121–6. 
73. Bauman A, Piel M, Schirrmacher R, Rösch F. Efficient alkali iodide promoted 18F-
fluoroethylations with 2-[18F]fluoroethyl tosylate and 1-bromo-2-[18F]fluoroethane. 
Tetrahedron Lett 2003;44:97–9. 
74. Piel M, Bauman A, Baum RP, et al. Improved automated synthesis of 
[18F]fluoroethylcholine as a radiotracer for cancer imaging. Bioorg Med Chem 
2007;15:3171–5. 
75. Schmaljohann J, Schirrmacher E, Wängler B, Wängler C, Schirrmacher R, Guhlke S. 
Fully automated SPE-based synthesis and purification of 2-[18F]fluoroethyl-choline for 
human use. Nuc Med Biol 2011;38(2): 165-70 
76. PA/PH/Exp. CRP/T (11) 2 ANP 
77. Asti M, Farioli D, Iori M, Guidotti C, Versari A, Salvo D. Efficient automated one-step 
synthesis of 2-[18F]fluoroethylcholine for clinical imaging: optimized reaction conditions 
and improved quality controls of different synthetic approaches. Nuc Med Biol 
2010:37(3);309-15 
78. Chi DY, Kilbourn MR, Katzenellenbogen JA and Welch MJ. A Rapid and Efficient 
Method for the Fluoroalkylation of Amines and Amides. Development of a Method Suitable 
for Incorporation of the Short-Lived Positron Emitting Radionuclide Fluorine-18 J. Org. 
Chem. 1987;52:658-664 
79. Musachio JL, Shah J and Pike VW. Radiosyntheses and Reactivities of Novel [18F]2-
fluoroethyl arylsulfonates. J Label Compd Radiopharm 2005;48:735–747. 
 66 
80.  Wadsak W, Mien LK, Ettlinger DE at al.  18F-fluoroethylations: different strategies for 
the rapid translation of 11C-methylated radiotracers Nuc Med Bio 2007;34:1019–1028 
81.  Kryza D, Tadinod V, Filannino MA,Villeret G, Lemoucheux G. Fully automated 
[18F]fluorocholine synthesis in the TracerLab MX FDG Coincidence synthesizer. Nuc Med 
Biol 35 (2008) 255–260 
82. Kwee S, Turner H, Lim J, Wakano C, Coel M. Dimethylaminoethanol reduces 
[18F]fluoroethylcholine uptake in prostate cancer cells. J Nucl Med 2006;47(Suppl 1):425P. 
83. Slaets D, De Bruyne S, Dumolyn C, Moerman L, Mertens K, De Vos F. Reduced 
dimethylaminoethanol in [18F]fluoromethylcholine: an important step towards enhanced 
tumour visualization Eur J Nucl Med Mol Imaging 2010;37:2136–45 
84.  Iwata R, Pascali C, Bogni A, Furumoto S, Terasaki K, Yanai K. [18F]-Fluoromethyl 
triflate, a novel and reactive [18F]fluoromethylating agent: preparation and application to 
the on-column preparation of [18F]fluorocholine. Appl Radiat Isot 2002;57:347–52. 
85. Mock BH, Winkle W, Vavrek MT. A color spot test for the detection of Kryptofix 2.2.2 in 
[18F]FDG preparations. Nucl Med Biol 1997;24:193–95. 
 
 
 
 
 
 
 
 
 
 
 
 67 
RINGRAZIAMENTI: 
 
… Lo sposo leva lo sguardo sull'accompagnatore che a braccia incrociate ha assistito alla 
scena e ora dice piano: «Per lo meno vi siete incontrati. L'avete già fatto più volte e lo 
farete sempre di nuovo. Questo non capita a tutti».  
Quindi segue la ragazza che a lunghi balzi s'inoltra nel deserto, in direzione dell'altra porta 
che si leva, enorme, sull'orizzonte settentrionale. Le due figure si fanno sempre più piccole 
in mezzo alle dune e presto di loro non resta che una traccia tortuosa di minuscoli crateri 
di sabbia. Lo sposo la segue con gli occhi lattiginosi, mentre con le dita palpa il boccio 
della rosa. «Com'è bella!» sussurra, «mio Dio, com'è bella!»  
E, lasciandosi ricadere sulla sabbia, mormora ancora: «Mi troverà laggiù, dietro quella 
porta?»  
Michael Ende “Lo specchio nello specchio” 
 
 
Innanzitutto vorrei ringraziare il Prof. Adriano Duatti che ha reso possibile questo dottorato 
di ricerca e in seguito la Dr.a Licia Uccelli, Dr.a Alessandra Boschi e Dr.a Micol Pasquali 
per la loro disponibilità e amicizia durante questo periodo.  
Questo lavoro di tesi è stato scritto grazie alla collaborazione delle persone che lavorano 
insieme a me. I loro sforzi e la loro dedizione nel portare avanti i progetti condivisi o 
semplicemente l’autonomia che hanno acquisito nell’attività quotidiana, ha permesso di 
dedicarmi alla rielaborazione dei dati raccolti e quindi alla stesura di questo studio. Grazie 
quindi a Daniela, Michele, Giulia e Pier Cesare: nei momenti di difficoltà o tensione hanno 
dimostrato di essere un gruppo che funziona, di fatto, un ottimo gruppo. 
 68 
 Un ringraziamento va, inoltre, agli amici con cui ho condiviso questi tre anni di vita, sia nei 
momenti di svago che in quelli di raccoglimento: Michele e Federica, Coscio e Elisa, 
Andrea e Sonia, Marco e Chiara, Vacca, è stato un piacere passare questi anni con voi. 
Un ultimo ringraziamento va a Montse perché riesce a fare una cosa semplice che però è 
la più importante … mi fa essere felice. 
Questa tesi di dottorato è dedicata a mio nipote Filippo, primo e per ora unico di una 
nuova generazione, perché ha il merito di aver portato in famiglia una comunione che da 
tanto tempo mancava. 
 
